European Leukemia Trial Registry
Trial: AZALE

More Details
Scientific Title A phase I study of a combination of 5-azacitidine followed by lenalidomide in high-risk MDS RAEB or relapsed/refractory AML patients with cytogenetic abnormalities including –5 or del(5q)
Short Title AZALE
Trialgroup Deutsche MDS
Type of Trial multicentric, single-group, open-label
Disease Myelodysplastic Syndrome(MDS) Intermedia II and high risk
Age >= 18 years
Status Closed
Start of Recruitment 30.10.2008
Leader Platzbecker, Prof. Dr. med., Uwe
Centre of Trial Universitätsklinikum Carl Gustav Carus, Dresden
Shortprotocol Shortprotocol

Genexpressionslabor der Med. Klinik III, Charité Universitätsmedizin Berlin, Campus Benjamin-Franklin

gene expression
Hämatologisches Labor, Universitätsklinikum Dresden

created 03.05.2011 Johannes Kraus
changed 05.11.2014 Alexandra Lucaciu
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |